Streetbeat News

Stock Prices

OMGA

HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating on Omega Therapeutics (NASDAQ:OMGA) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:18 pm

WST

West Pharmaceutical Servs (NYSE:WST) has seen a 13.47% decrease in short interest, with 941 thousand shares sold short, representing 1.67% of available shares. The average time to cover these short positions is 1.9 days. A decrease in short interest can indicate a more bullish sentiment towards the stock. WST has less short interest compared to its peer group average of 5.67%.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:15 pm

NTES

NetEase (NYSE:NTES) has seen a 12.77% increase in short interest since its last report, with 3.38 million shares sold short, representing 0.53% of its float. It would take about 3.47 days to cover these short positions based on average trading volume. While an increase in short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop. NetEase's short interest is below its peer group average of 3.88%.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:15 pm

MRVL

Marvell Tech (NYSE:MRVL) has experienced an 18.99% increase in short interest since its last report, with 15.55 million shares sold short, representing 2.13% of its float. It would take about 1.8 days to cover all short positions based on current trading volume. While an increase in short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop. Marvell Tech's short interest is below its peer group average of 3.62%.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:15 pm

TPR

JP Morgan analyst Matthew Boss has maintained an Overweight rating on Tapestry (NYSE:TPR) but reduced the price target from $56 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:05 pm

IWM

QQQ

SPY

Moody's has downgraded the US credit outlook from 'stable' to 'negative,' leading to a decline in major indexes.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:05 pm

KYMR

Kymera Therapeutics announced positive Phase 1 trial results for KT-474, published in Nature Medicine. KT-474, an IRAK4 degrader, showed robust degradation and pathway inhibition with a favorable safety profile in HS and AD patients. The trial indicated a reduction in inflammatory biomarkers and improvement in symptoms. Sanofi is conducting Phase 2 trials of KT-474 for HS and AD. Kymera's stock symbol is KYMR.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:04 pm

IMMR

Immersion Corporation (NASDAQ:IMMR) reported a decline in Q3 FY23 revenue by 32.3% year-over-year to $9.48 million, surpassing consensus estimates of $7.35 million. Royalty and license revenues decreased compared to the previous year, and adjusted EPS fell from $0.25 to $0.12. Operating income also declined by 40.4% Y/Y, with a reduced margin. IMMR repurchased shares and reduced operating expenses. The company announced a 50% increase in its quarterly dividend to $0.045 per share. Immersion is pursuing legal action against Meta Platforms, Inc. for alleged patent infringement. IMMR shares dropped by 7.23% to $6.22.

Portfolio Pulse from Akanksha Bakshi

November 13, 2023 | 4:02 pm

NRXP

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on November 14, 2023. Analysts predict an EPS of $-0.12. Investors will be looking for an earnings beat and positive guidance for future growth. Historically, NRXP's stock price has reacted to past earnings performances, with a mix of positive and negative changes post-announcement. The stock is currently trading at $0.3299, down 64.57% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:02 pm

PPSI

Pioneer Power Solutions (NASDAQ:PPSI) is expected to release its quarterly earnings report on Tuesday, 2023-11-14, with an estimated EPS of $0.05. Investors are looking for an earnings beat and positive guidance for the next quarter. In the past, PPSI's stock price has been affected by both earnings performance and guidance. Last quarter, PPSI missed the EPS estimate by $0.03 but saw an 11.32% increase in share price the following day. Over the last 52 weeks, PPSI shares have risen by 94.06%.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:02 pm